Cipla Ltd. — M&A Activity 2019

Nov 27, 2019

==> picture [111 x 38] intentionally omitted <==

==> picture [59 x 22] intentionally omitted <==

==> picture [72 x 76] intentionally omitted <==

Sr. No.	Particulars	Particulars	Details CiplaPharmaLanka(Private) Limited IthasturnoverofLKR3,244,483,618for the Financial endedon31'1March2019.
a)	Nameofthe target entity, details in brief suchassize,turnover etc.;
b)	Whether the acquisition would fall within related party transaction(s)andwhether the promoter/ promoter group/ group companies have any interestinthe entity being acquired?Ifyes,natureofinterest anddetails thereof and whether thesameis done at "arms' length";		Acquisition doesn't fall within the purviewofrelated party transactions. CiplaPharmaLankaisa subsidiaryofCiplaLimited.
c)	Industry to which the entity being acquired belongs;		Pharmaceutical business
d)	Objectsandeffectsofacquisition (including but not limited to, disclosureofreasons for acquisitionoftarget entity,ifits businessis outside the main lineofbusinessofthe listed entity);		Acquisitionof40%stakeinCiplaPharmaLankafrom CitiHealth Imports (Private) Limited. Thiswill result in terminationofshareholders' agreement dt.17thJune2014,amendedbya letter dated3'dMarch 2017, makingthe target entitya whollyowned subsidiary.
e)	Brief detailsofany governmental or regulatory approvals required tor the acquisition;		Not Applicable
f)	Indicative time-periodforcompletionofthe acquisition;		Thetransactionisexpected tobecompleted before101h December, 2019.
~~t--~~g)	Natureofconsideration - whethercash considerationorshare swapanddetailsof thesame;		Cashconsideration
h)	Costofacquisition or the price at which the sharesare acquired		CashconsiderationofLKR400,000tobepaidonclosing oftransaction.
i)	Percentage ofshareholding_I_control acquiredand_I_ornumberofshares acquired;		400,000issuedandpaid up capitalofLKR1per shareeach representing40%ofthe share capitalofCiplaPharma Lanka'sshare capitalona fully dilutedbasis.
j)
	Brief background about the intermsofproducts/lin	entity acquired eofbusiness	CiplaPharmaLankaisa private limited liability company incorporated inSriLankaon81hAugust,2014having a
	acquired, dateofincorpora last3years' turnover, coun acquired entityhaspresenc significant information (in br	tion, historyof tryinwhich the e and any other ief)	market shareof6.5%inSriLankanMarket. TheCompany was formedasajointventure between Cipla(EU)and CitiHealth Imports (Private) Limited to conduct the activityofmarketinganddistributionof pharmaceutical products. TheCompanyhasbeen consistently ranked amongst the top 3asper IQVIAandisthe Market Leader In Respiratory andUrology along with significant presenceinCardiaand Acute therapies. TheturnoverforFY17wasLKR2,608,451,783,for FY18itwasLKR3,136,112,558andforFY19itwas LKR3,244,483,618.

==> picture [76 x 76] intentionally omitted <==

==> picture [60 x 19] intentionally omitted <==